Trial · NCT01894022
Results by group504
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 504
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) | Previous Placebo | Any AE | 8 | Participants | |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) | Previous Ambrisentan | Any AE | 6 | Participants | |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) | Previous Placebo | Any SAE | 3 | Participants | |
| Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) | Previous Ambrisentan | Any SAE | 0 | Participants | |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Entry visit, n=9, 10 | -0.010 | Inter-Quartile Range -0.020 to 0.000 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Entry visit, n=9, 10 | 0.000 | Inter-Quartile Range -0.010 to 0.010 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Month 1, n=7, 10 | -0.010 | Inter-Quartile Range -0.010 to 0.000 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Month 1, n=7, 10 | 0.000 | Inter-Quartile Range -0.020 to 0.000 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Month 3, n=7, 8 | -0.010 | Inter-Quartile Range -0.020 to 0.010 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Month 3, n=7, 8 | 0.000 | Inter-Quartile Range -0.010 to 0.020 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Month 6, n=5, 6 | 0.000 | Inter-Quartile Range -0.020 to 0.000 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Month 6, n=5, 6 | 0.000 | Inter-Quartile Range -0.010 to 0.030 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Month 9, n=2, 5 | -0.025 | Inter-Quartile Range -0.040 to -0.010 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Month 9, n=2, 5 | -0.010 | Inter-Quartile Range -0.020 to -0.010 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Month 12, n=1, 3 | -0.020 | Inter-Quartile Range -0.020 to -0.020 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Month 12, n=1, 3 | 0.000 | Inter-Quartile Range -0.020 to 0.010 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, Month 15, n=0, 1 | NA | Inter-Quartile Range NA to NA | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, Month 15, n=0, 1 | -0.010 | Inter-Quartile Range -0.010 to -0.010 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Placebo | Basophils, End of study, n=8, 9 | -0.005 | Inter-Quartile Range -0.025 to 0.015 | Giga per Liter (GI/L) |
Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points | Previous Ambrisentan | Basophils, End of study, n=8, 9 | 0.000 | Inter-Quartile Range 0.000 to 0.000 | Giga per Liter (GI/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01894022/results